Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals

Jan 13 2014

• By Bridget Silverman

Related Content

FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials

Apr 08 2013

FDA Polled Review Staff On <em>Avandia</em> REMS Changes

Dec 02 2013

Ariad Took Dismissive View Of CV Events In <em>Iclusig</em> Labeling Proposals

Dec 17 2013

FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training

Nov 26 2013

Medical Advances Get More Chances When Safety Issues Arise

Nov 19 2013

Related Companies

Johnson & Johnson

Roche Holding AG

Otsuka Holdings Co., Ltd.

Novartis AG

AstraZeneca PLC

Pfizer Inc.

Pfizer Inc.

GSK plc

Biogen, Inc.

Elan Corporation

Bayer AG

Bausch Health Companies Inc.

Merck & Co., Inc.

Abbott

ARIAD Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Delcath Systems, Inc.

Additional Topics

Safety Risk Management Personalized Medicine Clinical Trials BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window